Highlights

  • Sonic Healthcare reported FY2026 Revenue of A$10.9 billion, underlying EBITDA of A$1.93 billion and underlying net profit of A$621 million.
  • Germany and Switzerland were key areas of laboratory integration and synergy capture during FY2026.
  • The group continued Investment in laboratory infrastructure, digital systems and operational consolidation across major markets.
  • Swiss operations recorded further laboratory mergers, while Germany progressed integration work across multiple functions.
  • Cost control, advanced diagnostics and operational efficiencies remained central to the group’s FY2026 performance.

Sonic Healthcare Limited (ASX:SHL) is one of the world’s largest medical diagnostics companies, providing laboratory medicine and diagnostic imaging services to medical practitioners, hospitals, community health services and patients. During FY2026, the group’s operating agenda centred on integrating acquired laboratory networks, capturing efficiencies in Germany and Switzerland, advancing laboratory infrastructure and maintaining growth across its core diagnostic businesses.

European Integration Becomes a Key Operating Theme

Sonic’s FY2026 reporting highlighted continued integration activity across its European laboratory businesses. In Germany, the group progressed the integration of the LADR laboratory group across sales, logistics, technical maintenance, information technology and financial systems. Management also completed extensive work to combine LADR capabilities with Sonic’s broader German platform. Germany recorded statutory revenue growth of 43%, including organic growth of 5%, supported by advanced diagnostics and other specialised testing services.

Swiss Laboratory Consolidation Advances

In Switzerland, Sonic reported organic growth of 4% in constant currency, with growth accelerating in the second half. The group continued to realise synergies from the integration of the SYNLAB Suisse and Dr Risch businesses. Four laboratory mergers were completed across Geneva, Lausanne, Zurich and Ticino during FY2026, while further optimisation work continued across procurement, logistics, sales, information technology and external reference testing. The integration programme is intended to simplify operations and improve laboratory efficiency across the national network.

Technology and Infrastructure Support Efficiency

Operational efficiency remained an important focus across Sonic’s wider laboratory network. In Australia, the company completed a major national laboratory platform procurement process and continued work on its new Docklands hub laboratory in Melbourne. Sonic also reported a significant programme to modernise its global digital infrastructure. These initiatives sit alongside ongoing use of laboratory automation, specialised diagnostic technology and digital workflow systems to support processing capacity, clinical service delivery and cost discipline.

FY2026 Financial Performance Reflects Broader Scale

Sonic reported FY2026 revenue of A$10.9 billion, underlying EBITDA of A$1.93 billion and underlying net profit of A$621 million. The company said organic revenue growth was 5% for the year, with advanced diagnostics contributing to growth. Germany and Switzerland recorded Margin expansion during FY2026, supported by operating leverage, Acquisition synergies and cost discipline. The results also reflected the contribution of newly integrated businesses and continued efforts to improve productivity across existing operations.

Operational Factors Remain Important

Sonic continues to operate across healthcare systems with different funding structures, reimbursement settings and labour conditions. In FY2026, Switzerland faced regulatory fee changes affecting selected high-volume tests, while labour and operating costs remained important considerations across multiple markets. Integration execution also requires coordination across laboratory systems, logistics, technology and clinical workflows. These factors make delivery against integration plans and cost programmes relevant measures of operational progress.

Key Insights

Sonic Healthcare’s FY2026 performance shows how integration, laboratory consolidation and technology investment are being used to support a geographically diversified diagnostics platform. Germany and Switzerland remain important areas for synergy capture, while Australian infrastructure and global digital programmes provide additional avenues for efficiency. Future reporting will provide further evidence on the pace of integration, operating cost discipline and the contribution of specialised diagnostics across the group.